Genetic differences in the antinociceptive effect of morphine and its potentiation by dextromethorphan in rats

Neuroscience Letters

Volumn 263, Issue 1, 1999, Pages 53-56

  Plesan, Aida ^a   Hoffmann, Orsolya ^a,b   Xu, Xiao Jun ^a   Wiesenfeld Hallin, Zsuzsanna ^a  

^a Div Clin Neurophysiol   (Sweden)

^b Stockholm Center for Dependency Disorders   (Sweden)

Author keywords

Analgesia; Dark Agouti; Nociception; Pain; Spontaneously Hypertensive; Sprague Dawley; Wistar Kyoto

Indexed keywords

DEXTROMETHORPHAN; MORPHINE;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; HOT PLATE TEST; HYPERALGESIA; MALE; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; STRAIN DIFFERENCE; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; DEXTROMETHORPHAN; DRUG SYNERGISM; HEAT; HYPERALGESIA; MALE; MORPHINE; NOCICEPTORS; PAIN; RATS; RATS, INBRED STRAINS; RATS, INBRED WKY; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY;

EID: 0033583121     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(99)00109-3     Document Type: Article

References (26)

1. Al-Dabbagh S.G., Idle J.R., Smith R.L. Animal modelling of human polymorphic drug oxidation-the metabolism of debrisoquine and phenacetin in rat inbred strains. J. Pharm. Pharmacol. 33:1981;161-164.
2. Bertilsson L., Dahl M.-L. Polymorphic drug oxidation: Relevance to the treatment of psychiatric disorders. CNS Drugs. 5:1996;200-223.
3. Cleary J., Mikus G., Somogyi A., Bochner F. The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley/Dark-Agouti rat model. J. Pharmacol. Exp. Ther. 271:1994;1528-1534.
4. Dayer P., Leemann T., Striberini R. Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450db1 activity. Clin. Pharmacol. Ther. 45:1989;34-40.
5. Elliott K., Hynansky A., Inturrissi C.E. Dextromethorphan attenuates and reverses analgesic tolerance to morphine. Pain. 59:1994;361-368.
6. Grass S., Hoffmann O., Xu X.-J., Wiesenfeld-Hallin Z. N-Methyl-D-aspartate receptor antagonists potentiate morphine's antinociceptive effect in the rat. Acta Physiol. Scand. 158:1996;269-273.
7. Hoffmann O., Plesan A., Wiesenfeld-Hallin Z. Genetic differences in morphine sensitivity, tolerance and withdrawal in rats. Brain Res. 806:1998;232-237.
8. Hoffmann O., Wiesenfeld-Hallin Z. Dextromethorphan potentiates morphine antinociception, but does not reverse tolerance in rats. NeuroReport. 7:1996;838-840.
9. Laulin J.P., Larcher A., Célèrier E., Le Moal M., Simmonet G. Long-lasting increased pain sensitivity in rat following exposure to heroin for the first time. Eur. J. Neurosci. 10:1998;782-785.
10. Lutfy K., Sadowski B., Kwon I.S., Weber E. Morphine analgesia and tolerance in mice selectively bred for divergent swim stress-induced analgesia. Eur. J. Pharmacol. 265:1994;171-174.
11. Lufty K., Hurlbut D.E., Weber E. Blockade of morphine induced analgesia and tolerance in mice by MK-801. Brain Res. 616:1993;83-88.
12. Maixner W., Touw K.B., Brody M.J., Gebhart G.F., Long J.P. Factors influencing the altered pain perception in the spontaneously hypertensive rat. Brain Res. 237:1982;137-145.
13. Mao J., Price D.D., Mayer D.J. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain. 62:1995;259-274.
14. Mao J., Price D.D., Caruso F.S. Oral administration of dextromethorphan prevents the development of morphine tolerance and dependence in rats. Pain. 67:1996;361-368.
15. Marek P., Ben-Eliyahu S., Gold M. Excitatory acid antagonists (kynurenic acid and MK-801) attenuate the development of morphine tolerance in the rat. Brain Res. 547:1991;77-81.
16. Okamoto K., Aoki K. Development of a strain of spontaneously hypertensive rats. Jpn. Circul. J. 27:1963;282-293.
17. Saavedra J.M. Naloxone reversible decrease in pain sensitivity in young and adult spontaneously hypertensive rats. Brain Res. 209:1981;245-249.
18. Tiseo P.J., Inturrissi C.E. Attenuation and reversal of morphine tolerance by the competitive N-methyl-D-aspartate receptor antagonist LY 274614. J. Pharmacol. Exp. Ther. 264:1993;1090-1096.
19. Tortella F.C., Pellicano M., Bowery N.G. Dextromethorphan and neuromodulation: old drug coughs up new activities. Trends Pharmacol. Sci. 10:1989;501-507.
20. Trujillo K.A., Akil H. Inhibition of morphine tolerance and dependence by the NMDA antagonist MK-801. Science. 251:1991;85-87.
21. Vaccarino A.L., Couret L.C. Jr. Relationship between hypothalamic-pituitary-adrenal activity and blockade of tolerance to morphine analgesia by pain: a strain comparison. Pain. 63:1995;385-389.
22. Wiesenfeld-Hallin Z. Combined opioid-MDA antagonist therapies. What advantages do they offer for the control of pain syndromes? Drugs. 55:1998;1-4.
23. Yamamoto Y., Tasaki T., Nakamura A., Iwata H., Kazusaka A., Gonzalez F.J., Fujita S. Molecular basis of the Dark Agouti rat drug oxidation polymorphism: importance of CYP2D1 and CYP2D2. Pharmacogenetics. 8:1998;73-82.
24. Zamir N., Segal M., Simantov R. Opiate receptor binding in the brain of the hypertensive rat. Brain Res. 213:1981;217-222.
25. Zieglgänsberger W., Tölle T.R. The pharmacology of pain signalling. Curr. Opin. Neurobiol. 3:1993;611-618.
26. Zysset T., Zeugin T., Kupfer A. In vivo and in vitro dextromethorphan metabolism in SD and DA rat. An animal model of the debrisoquine-type polymorphic oxidation in man. Biochem. Pharmacol. 37:1988;3155-3160.